Wisp and Mount Sinai just launched a PrEP delivery model to close the “not solved” gap

PrEP prevents HIV by 99%. That single sentence is the entire plot twist in HIV prevention. The drug works. The barrier has never been chemistry. It has been the messy, real-world work of getting the right people on the right regimen, consistently, and safely enough to actually reduce infections at scale.

That is why Wisp and Mount Sinai launching a new model to “deliver” PrEP matters. The development is framed as a delivery problem, not a medical one. In other words, this is not another “we found a better pill” story. It is an operational reckoning with what happens after a clinical breakthrough meets the outside world: scheduling, follow-through, adherence, patient experience, and the friction that quietly makes prevention fail.

To understand why delivery is the main battlefield, it helps to remember how HIV prevention typically succeeds in theory but struggles in practice. A prevention regimen can look simple in a trial. Then it meets the lived reality of patients and providers. People have to initiate care, complete baseline steps, maintain ongoing use, and show up for follow-up. Clinicians have to find time, coordinate labs, and keep the workflow from breaking. Systems have to support the patient journey without turning it into a scavenger hunt.

PrEP’s 99% prevention rate is a powerful anchor because it strips away an excuse that often shows up in boardrooms and budgets. When the drug is already highly effective, a new program can be judged by whether it increases uptake and continuity. That is a different kind of success metric than drug development. It is about reach, retention, and reduction in real-world transmission. Those are harder to measure quickly, but they are the metrics that ultimately determine whether prevention is truly “solved” outside academic settings.

There is also a regulatory and market context executives should recognize. HIV prevention has long been intertwined with public health policy, insurer behavior, and provider operations. Any model that touches initiation and ongoing prescribing runs into the same practical constraints: who can prescribe, what monitoring is required, how documentation flows, and how follow-up is sustained. Even when clinicians and patients are motivated, administrative friction can turn a good plan into a delayed plan. Delivery-focused models often aim to streamline that chain.

This is where Wisp and Mount Sinai’s move signals strategic intent. Wisp is positioned to tackle the patient journey, while Mount Sinai brings clinical credibility and operational muscle in care settings. When a hospital system collaborates with a delivery-oriented company, the goal is usually to reduce drop-off points and standardize the experience. The story as presented is explicit about the mission: a new delivery model to fix how PrEP gets delivered.

For decision-makers, the second-order implication is that the next wave of impact in prevention may come from distribution networks and care pathways, not from new molecules. When the evidence says PrEP prevents HIV by 99%, the competitive advantage shifts. It goes to whoever can run the pipeline better: identify eligible patients, reduce time to initiation, keep adherence steady, and make follow-up routine instead of optional.

That also changes what boards should ask for. If the barrier is delivery, then dashboards should reflect delivery performance, not just program activity. Executives should look for indicators like time-to-start, persistence over time, and the ability to reach populations that historically face access challenges. The strategic stakes are immediate for peers because prevention programs are measured on outcomes, and outcomes depend on operational execution.

Bottom line: PrEP’s effectiveness is not the remaining mystery. The remaining question is whether systems can deliver it reliably enough to turn near-perfect clinical efficacy into population-level protection. Wisp and Mount Sinai are betting that fixing the delivery gap is the fastest path from “solved” in a study to “solved” in the real world.